{"commentary":{"count":31,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":15,"x_thread":11,"podcast":5},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03267433\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NCT03267433","nct_id":"NCT03267433","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct03267433. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Patients receive standard of care preparative chemotherapy and undergo auto-HCT. Beginning 100-140 days after transplant, patients receive rituximab IV or rituximab and hyaluronidase human SC or any approved rituximab biosimilar at the approved dose once every 8 weeks for up to 18 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo PET, CT or PET/CT throughout the study. Patients may undergo blood sample collection during screening and on study. Patients also may undergo bone marrow biopsy and aspirate during screening.","label":"Group I (auto-HCT, rituximab)","type":"EXPERIMENTAL"},{"description":"Patients receive standard of care induction chemotherapy. Beginning 40-180 days after completion of chemotherapy, patients receive rituximab or rituximab and hyaluronidase human or any approved rituximab biosimilar at the approved dose, as in Group I. Patients undergo PET, CT or PET/CT throughout the study. Patients may undergo blood sample collection during screening and on study. Patients also may undergo bone marrow biopsy and aspirate during screening.","label":"Group II (rituximab)","type":"EXPERIMENTAL"}],"collaborators":["National Cancer Institute (NCI)"],"completion_date":{"date":"2027-01-31","type":"ESTIMATED"},"conditions":["Mantle Cell Lymphoma"],"enrollment":{"count":689,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Autologous Hematopoietic Stem Cell Transplantation","type":"PROCEDURE"},{"name":"Biospecimen Collection","type":"PROCEDURE"},{"name":"Bone Marrow Aspirate","type":"PROCEDURE"},{"name":"Bone Marrow Biopsy","type":"PROCEDURE"},{"name":"Computed Tomography","type":"PROCEDURE"},{"name":"Positron Emission Tomography","type":"PROCEDURE"},{"name":"Rituximab","type":"BIOLOGICAL"},{"name":"Rituximab and Hyaluronidase Human","type":"BIOLOGICAL"}],"last_update":"2026-09-14","lead_sponsor":"ECOG-ACRIN Cancer Research Group","official_title":"A Randomized Phase III Trial of Consolidation With Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs Maintenance Rituximab Alone for Patients With Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2027-01-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Overall survival (OS) in mantle cell lymphoma (MCL) patients in minimal residual disease (MRD)-negative complete remission (CR) who undergo auto-hematopoietic stem cell transplant (HCT) followed by rituximab versus (vs.) maintenance rituximab alone","timeFrame":"Time between randomization and death from any cause, assessed up to 10 years"}],"references":[{"citation":"Kumar A. What is the role of up-front autologous stem cell transplantation in mantle cell lymphoma? Hematology Am Soc Hematol Educ Program. 2022 Dec 9;2022(1):155-162. doi: 10.1182/hematology.2022000333.","pmid":"36485104","type":"DERIVED"},{"citation":"Thiruvengadam SK, Hunter B, Varnavski A, Fakhri B, Kaplan L, Ai WZ, Pampaloni M, Huang CY, Martin T 3rd, Damon L, Andreadis CB. Ofatumumab, Etoposide, and Cytarabine Intensive Mobilization Regimen in Patients with High-risk Relapsed/Refractory Diffuse Large B-Cell Lymphoma Undergoing Autologous Stem Cell Transplantation. Clin Lymphoma Myeloma Leuk. 2021 Apr;21(4):246-256.e2. doi: 10.1016/j.clml.2020.11.005. Epub 2020 Nov 11.","pmid":"33288485","type":"DERIVED"}],"start_date":{"date":"2017-11-27","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission","url":"https://clinicaltrials.gov/study/NCT03267433"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct03267433"}